Surgery Partners, Inc. (SGRY)
NASDAQ: SGRY · Real-Time Price · USD
23.94
+0.30 (1.27%)
At close: May 16, 2025, 4:00 PM
23.94
0.00 (0.00%)
After-hours: May 16, 2025, 7:13 PM EDT
Surgery Partners Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Surgery Partners stock ranges from a low of $28 to a high of $43. The average analyst price target of $35.43 forecasts a 47.99% increase in the stock price over the next year.
Price Target: $35.43 (+47.99%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Surgery Partners stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +46.20% | Apr 21, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $35 | Buy | Reiterates | $35 | +46.20% | Mar 25, 2025 |
| Macquarie | Macquarie | Buy Maintains $34 → $33 | Buy | Maintains | $34 → $33 | +37.84% | Mar 11, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $38 → $28 | Hold | Maintains | $38 → $28 | +16.96% | Dec 3, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $49 → $35 | Buy | Maintains | $49 → $35 | +46.20% | Nov 20, 2024 |
Financial Forecast
Revenue This Year
3.45B
from 3.11B
Increased by 10.88%
Revenue Next Year
3.77B
from 3.45B
Increased by 9.21%
EPS This Year
1.03
from -1.33
EPS Next Year
1.37
from 1.03
Increased by 32.89%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.6B | 4.0B | 4.5B | ||
| Avg | 3.5B | 3.8B | 4.2B | ||
| Low | 3.3B | 3.6B | 3.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.2% | 16.9% | 20.0% | ||
| Avg | 10.9% | 9.2% | 11.3% | ||
| Low | 6.1% | 3.1% | 3.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.38 | 1.79 | 2.14 | ||
| Avg | 1.03 | 1.37 | 1.66 | ||
| Low | 0.48 | 0.81 | 1.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 72.9% | 56.1% | ||
| Avg | - | 32.9% | 21.0% | ||
| Low | - | -21.2% | -15.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.